---
title: Reduce off time and fluctuations
nct_id: NCT07219927
status: RECRUITING
sponsor: Supernus Pharmaceuticals, Inc.
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07219927"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07219927"
last_fetched: "2026-05-10T14:06:41.216Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce off time and fluctuations

**Goal (in five words):** Reduce off time and fluctuations

**Official Title:** Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease

**Trial ID:** [NCT07219927](https://clinicaltrials.gov/study/NCT07219927)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Supernus Pharmaceuticals, Inc.
- **Target Enrollment:** 120 participants
- **Start Date:** 2025-03-31
- **Completion Date:** 2027-08-01
- **Conditions:** Parkinson Disease
- **Interventions:** Observational study
- **Intervention Types:** OTHER

## Summary For Families

The goal is to collect real-world patient experiences with continuous subcutaneous apomorphine infusion (ONAPGO) in the United States, to learn how it affects motor fluctuations, off time, and overall tolerability in routine care. ONAPGO delivers apomorphine, a fast-acting dopamine agonist, as a steady under-the-skin infusion to stimulate dopamine receptors and smooth out levodopa wearing-off and sudden off periods, and it is often used alongside levodopa, but it can interact dangerously with 5-HT3 antagonist antiemetics and can cause reactions in people with sulfite sensitivity. Adults 18 and older who have already been prescribed ONAPGO and who opt into support from a Clinical Nurse Navigator are eligible, while those the clinician deems inappropriate, those taking 5-HT3 antagonists, or those with known apomorphine or sulfite allergy are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

Participant has received a prescription for ONAPGO™ according to the standard of care.

Participant has opted into receiving support services from the Clinical Nurse Navigator (CNN), a registered nurse specially trained to work with persons with Parkinson's disease, as noted on the Prescription Enrollment Form.

The HCP/Investigator determines the participant is an appropriate study participant.

Participant is able and willing to provide informed consent (or informed assent form \[IAF\], as applicable) and signs the consent form on the Enrollment Day.

Exclusion Criteria:

Did not receive a prescription for ONAPGO™.

Prescribed ONAPGO™, but the HCP/Investigator determines the participant should not participate in this observational study.

Concomitant use of ONAPGO™ with 5-HT3 antagonists, including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) or alosetron.

Known hypersensitivity to apomorphine or to excipients of ONAPGO™, including sulfite (e.g., sodium metabisulfite).
```

## Locations (5)

- Parkinson's Disease and Movement Disorders Center - Orange County (South), Aliso Viejo, California, United States _(33.5650, -117.7271)_
  - Mindy Bixby, D.O. — (CONTACT)
  - Mindy Bixby, D.O. — (PRINCIPAL_INVESTIGATOR)
- Parkinson's Disease and Movement Disorders Center - Orange County (North), Irvine, California, United States _(33.6695, -117.8231)_
  - Sandeep Thakkar, D.O. — (CONTACT)
  - Sandeep Thakkar, D.O. — (PRINCIPAL_INVESTIGATOR)
- Parkinson's Research Centers of America - Palo Alto, Palo Alto, California, United States _(37.4419, -122.1430)_
  - Salima Brillman, MD — (CONTACT)
  - Salima Brillman, MD — (PRINCIPAL_INVESTIGATOR)
- Parkinson's Disease & Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States _(26.3587, -80.0831)_
  - Stuart Isaacson, MD — (CONTACT)
  - Stuart Isaacson, MD — (PRINCIPAL_INVESTIGATOR)
- Parkinson's Disease and Movement Disorders Center - Long Island, Commack, New York, United States _(40.8429, -73.2929)_
  - David Kreitzman, M.D. — (CONTACT)
  - David Kreitzman, M.D. — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Mindy Grall, PhD ANP-BC — (CONTACT) — 18663980833 — mgrall@supernus.com
- Supernus Supernus — (CONTACT) — 18663980833

---

*Canonical: https://parkinsonspathways.com/trial/NCT07219927*  
*HTML version: https://parkinsonspathways.com/trial/NCT07219927*  
*Source data: https://clinicaltrials.gov/study/NCT07219927*